Celcuity (NASDAQ:CELC) Stock Price Up 7.7% – Should You Buy?

Shares of Celcuity, Inc. (NASDAQ:CELC) traded up 7.7% during trading on Tuesday . The stock traded as high as $111.84 and last traded at $111.7840. Approximately 1,098,396 shares changed hands during mid-day trading, an increase of 7% from the average daily volume of 1,029,468 shares. The stock had previously closed at $103.79.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CELC. Citigroup restated a “market outperform” rating on shares of Celcuity in a research report on Thursday, May 28th. Citizens Jmp boosted their target price on Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a research report on Monday, May 4th. Craig Hallum dropped their price target on Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Stifel Nicolaus set a $150.00 price target on Celcuity in a report on Monday, May 4th. Finally, Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $152.09.

Celcuity Stock Up 7.8%

The company has a market cap of $5.46 billion, a PE ratio of -28.76 and a beta of 0.16. The company has a fifty day moving average of $111.44 and a two-hundred day moving average of $111.07. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, analysts anticipate that Celcuity, Inc. will post -3.69 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares in the company, valued at $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by company insiders.

Institutional Trading of Celcuity

Institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its position in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the period. US Bancorp DE raised its holdings in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after buying an additional 1,167 shares during the period. Parallel Advisors LLC bought a new stake in shares of Celcuity during the 1st quarter worth approximately $38,000. Finally, Meeder Asset Management Inc. bought a new stake in shares of Celcuity during the 4th quarter worth approximately $42,000. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.